sábado, 31 de octubre de 2020
Portal de Infomed
 
 
Total de artículos: 150 mostrando: 71 - 80

página 8 de 15   1  2  3  4  5  6  7  8  9  10  
Titulares

Allogeneic Mesenchymal Precursor Cells in Type 2 Diabetes

1.    Jay S. Skyler(1),Vivian A. Fonseca(2), Karen R. Sega(3),  Julio Rosenstock(4),
on behalf of the MSB-DM003 Investigators
Author Affiliations
1).-Diabetes Research Institute, University of Miami, Miami, FL
2).-Tulane University Health Sciences Center, New Orleans, LA
3).-Mesoblast Inc., New York, NY
4).-Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX
Corresponding author: Jay S. Skyler, jskyler@med.miami.edu.

Abstract
OBJECTIVE To assess the safety, tolerability, and feasibility of adult allogeneic bone marrow?derived mesenchymal precursor cells (MPCs) in type 2 diabetes inadequately controlled with metformin either alone or with one additional oral antidiabetic agent.
RESEARCH DESIGN AND METHODS The study was a dose-escalating randomized placebo-controlled trial assessing one intravenous (IV) infusion of MPCs (rexlemestrocel-L; Mesoblast Inc.) 0.3 × 106/kg (n = 15), 1.0 × 106/kg (n = 15), or 2.0 × 106/kg (n = 15) or placebo (n = 16). Study duration was 12 weeks.
RESULTS Subjects (21 women, 40 men) with a mean ± SD baseline HbA1c 8.3 ± 1.0% (67 ± 10.9 mmol/mol), BMI 33.5 ± 5.5 kg/m2, and diabetes duration 10.1 ± 6.0 years were enrolled at 18 U.S. sites. No acute adverse events (AEs) were associated with infusion. No serious AEs, serious hypoglycemia AEs, or discontinuations due to AEs over 12 weeks were found. No subjects developed donor-specific anti-HLA antibodies or became sensitized. The safety profile was comparable among treatment groups. Compared with placebo, a single IV infusion of rexlemestrocel-L reduced HbA1c at all time points after week 1. The adjusted least squares mean ± SE dose-related differences in HbA1c from placebo in the rexlemestrocel-L groups ranged from ?0.1 ± 0.2% (?1.1 ± 2.2 mmol/mol) to ?0.4 ± 0.2% (4.4 ± 2.2 mmol/mol) at 8 weeks and from 0.0 ± 0.25% to ?0.3 ± 0.25% (?3.3 ± ?2.7 mmol/mol) at 12 weeks (P < 0.05 for 2.0 × 106/kg dose at 8 weeks). The clinical target HbA1c <7% (53 mmol/mol) was achieved by 33% (5 of 15) of the subjects who received the 2.0 × 106/kg dose vs. 0% of those who received placebo (P < 0.05).
CONCLUSIONS This short-term study demonstrates the safety and feasibility of up to 246 million MPCs in subjects with type 2 diabetes.
http://care.diabetesjournals.org/content/early/2015/07/01/dc14-2830.abstract


 
Total de artículos: 150 mostrando: 71 - 80

página 8 de 15   1  2  3  4  5  6  7  8  9  10  
 
: Editor principal, Especialista de II Grado en Endocrinología - | Instituto de Endocrinología - MINSAP | 29 y D, Plaza, Ciudad de La Habana, 10400, Cuba. | Telefs: (537) 8382453, Horario de atención: 8:00 a.m. a 4:00 p.m., de Lunes a Viernes



Nosotros suscribimos Los Principios del código HONcode de la Fundación Salud en la Red
 Nosotros suscribimos
 los Principios
 HONcode.
 Compruébelo aquí
Webs Médicas de Calidad Contenido Digital Cubano 2005 Premio Stockholm Challenge 2002